https://mindmedicinelaw.com/briefing/psychedelic-trial-participants-challenge-clinical-protocols-20261017-51042The Psychedelic Journalen2026-10-17T15:06:44.591755+00:00Psychedelic Trial Participants Challenge Clinical Protocolspsychedelic clinical trials, participant experience, integration support, outcome measures, FDA guidance, patient-centered research, MDMA trials, trial design limitations, ethics in researchhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-centers-face-scrutiny-over-therapy-standards-20261016-51212The Psychedelic Journalen2026-10-17T22:04:35.692573+00:00Oregon’s Psilocybin Centers Face Scrutiny Over Therapy Standardsoregon psilocybin centers, psychedelic therapy standards, measure 109, clinical integration, regulatory oversight, undercover investigation, public health risk, facilitator training, policy implications, psychedelic-assisted carehttps://mindmedicinelaw.com/briefing/esketamine-and-wnt4-signaling-preclinical-insights-from-rat-pain-depression-mode-20261016-50978The Psychedelic Journalen2026-10-17T15:07:00.876965+00:00Esketamine and Wnt4 Signaling: Preclinical Insights from Rat Pain-Depression Modelsesketamine, pain-depression dyad, wnt4 signaling, anterior cingulate cortex, preclinical research, transcriptomics, molecular mechanisms, clinical translation, psychedelic neurosciencehttps://mindmedicinelaw.com/briefing/ketamine-s-synaptic-and-monoaminergic-effects-in-human-ipsc-neurons-20261016-50979The Psychedelic Journalen2026-10-17T15:05:29.239434+00:00Ketamine’s Synaptic and Monoaminergic Effects in Human iPSC Neuronsketamine, iPSC-derived neurons, synaptic remodeling, monoaminergic signaling, antidepressant mechanisms, precision psychiatry, translational neuroscience, akt pathway, drug development, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/ibogaine-5-meo-dmt-adverse-outcomes-us-survey-insights-20261016-50964The Psychedelic Journalen2026-10-17T15:05:13.712439+00:00Ibogaine, 5-MeO-DMT Adverse Outcomes: US Survey Insightsibogaine adverse effects, 5-meo-dmt safety, psychedelic survey, cardiac risk psychedelics, clinical trial design, psychedelic regulation, self-reported outcomes, public health, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/belgium-considers-regulated-psychedelic-therapy-access-for-depression-20261016-50705The Psychedelic Journalen2026-10-16T15:05:56.707181+00:00Belgium Considers Regulated Psychedelic Therapy Access for Depressionbelgium psychedelic policy, treatment-resistant depression, psychedelic therapy europe, real-world evidence, clinical access psychedelics, mental health regulation, psilocybin mdma belgium, eu regulatory framework, psychiatric innovationhttps://mindmedicinelaw.com/briefing/controlled-vocabulary-gaps-in-depression-biomarker-indexing-implications-for-psy-20261015-50981The Psychedelic Journalen2026-10-17T15:07:16.536875+00:00Controlled Vocabulary Gaps in Depression Biomarker Indexing: Implications for Psychedelic Trialsmesh indexing, biomarker sampling site, depression research, psychedelic clinical trials, systematic review bias, inflammatory endotype, regulatory evidence, bibliographic infrastructure, meta-research, controlled vocabularyhttps://mindmedicinelaw.com/briefing/ketamine-induced-cystitis-clinical-risks-and-policy-implications-20261015-50984The Psychedelic Journalen2026-10-17T15:06:12.117387+00:00Ketamine-Induced Cystitis: Clinical Risks and Policy Implicationsketamine-induced cystitis, bladder toxicity, recreational ketamine use, medical ketamine risks, urothelial inflammation, clinical management, policy implications, addiction medicine, urological complications, evidence gapshttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-alters-dna-methylation-in-mdd-patients-20261015-50950The Psychedelic Journalen2026-10-17T15:05:57.459781+00:00Ketamine-Assisted Psychotherapy Alters DNA Methylation in MDD Patientsketamine-assisted psychotherapy, dna methylation, major depressive disorder, notch signaling pathway, biomarker development, psychedelic research, clinical trials, molecular mechanisms, regulatory sciencehttps://mindmedicinelaw.com/briefing/emotional-bias-markers-and-esketamine-response-in-trd-clinical-implications-20261015-50982The Psychedelic Journalen2026-10-17T15:05:41.881532+00:00Emotional Bias Markers and Esketamine Response in TRD: Clinical Implicationsesketamine, treatment-resistant depression, emotional bias, response criterion, clinical response markers, psychedelic therapy, measurement-based care, precision psychiatry, nmda antagonist, depression biomarkershttps://mindmedicinelaw.com/briefing/defining-psychotherapy-vs-support-in-psychedelic-trials-policy-and-research-impl-20261015-50632The Psychedelic Journalen2026-10-16T15:08:24.186305+00:00Defining Psychotherapy vs. Support in Psychedelic Trials: Policy and Research Implicationspsychedelic clinical trials, psychotherapy definition, psychological support, trial design standards, regulatory approval, reproducibility, cross-study comparison, fda guidance, risk of bias, clinical trial reportinghttps://mindmedicinelaw.com/briefing/global-depression-trends-and-novel-interventions-policy-and-research-context-20261015-50643The Psychedelic Journalen2026-10-16T15:08:01.360220+00:00Global Depression Trends and Novel Interventions: Policy and Research Contextglobal depression trends, ketamine esketamine interventions, digital therapeutics, public health policy, treatment-resistant depression, mental health disparities, neuroinflammation, youth mental health, regulatory frameworkshttps://mindmedicinelaw.com/briefing/colorado-police-raids-highlight-legal-risks-in-psilocybin-and-thc-sales-20261015-50706The Psychedelic Journalen2026-10-16T15:07:04.990279+00:00Colorado Police Raids Highlight Legal Risks in Psilocybin and THC Salescolorado springs, psilocybin law, thc enforcement, police raids, psychedelic policy, natural medicine health act, cannabis regulation, legal risks, market barriershttps://mindmedicinelaw.com/briefing/ethical-lessons-from-psilocybin-therapy-in-advanced-cancer-care-20261015-50633The Psychedelic Journalen2026-10-16T15:06:42.402049+00:00Ethical Lessons from Psilocybin Therapy in Advanced Cancer Carepsilocybin-assisted therapy, advanced cancer, palliative care, informed consent, clinical ethics, aspirational autonomy, oncology, existential outcomes, candidate selection, psychedelic clinical trialshttps://mindmedicinelaw.com/briefing/ibogaine-review-for-substance-use-disorders-2026-pubmed-update-20261014-51022The Psychedelic Journalen2026-10-17T15:07:31.875042+00:00Ibogaine Review for Substance Use Disorders: 2026 PubMed Updateibogaine, substance use disorders, psychedelic research, clinical trials, pharmacogenetics, regulatory policy, public health, safety risks, addiction treatment, neurobiologyhttps://mindmedicinelaw.com/briefing/group-psilocybin-retreats-and-social-connection-case-insights-20261014-50975The Psychedelic Journalen2026-10-17T15:06:28.337306+00:00Group Psilocybin Retreats and Social Connection: Case Insightspsilocybin, group therapy, psychedelic retreats, social connectedness, clinical trials, regulatory policy, community models, mental health, safety protocols, observational studieshttps://mindmedicinelaw.com/briefing/ayahuasca-regulation-and-ancestral-medicine-in-pastaza-ecuador-20261014-50595The Psychedelic Journalen2026-10-16T15:09:01.696736+00:00Ayahuasca Regulation and Ancestral Medicine in Pastaza, Ecuadorayahuasca regulation, ancestral medicine, ecuador health policy, indigenous rights, pastaza amazon, traditional knowledge protection, intercultural health, public health risks, legal framework, community-driven policyhttps://mindmedicinelaw.com/briefing/ayahuasca-health-risks-consumer-survey-underscores-need-for-regulation-20261014-50596The Psychedelic Journalen2026-10-16T15:08:42.464512+00:00Ayahuasca Health Risks: Consumer Survey Underscores Need for Regulationayahuasca health risks, unsupervised psychedelic use, harm reduction, medical screening, regulatory oversight, consumer survey, traditional vs commercial use, psychedelic policy, mental health effects, indigenous practiceshttps://mindmedicinelaw.com/briefing/ibogaine-s-clinical-promise-and-peril-for-substance-use-disorders-20261014-50598The Psychedelic Journalen2026-10-16T15:07:41.670106+00:00Ibogaine’s Clinical Promise and Peril for Substance Use Disordersibogaine, substance use disorder, psychedelic therapy, clinical trials, cardiotoxicity, noribogaine, regulatory policy, addiction treatment, safety protocolshttps://mindmedicinelaw.com/briefing/blood-brain-barrier-dysfunction-in-trd-new-evidence-for-network-disruption-20261014-50647The Psychedelic Journalen2026-10-16T15:07:23.246285+00:00Blood-Brain Barrier Dysfunction in TRD: New Evidence for Network Disruptionblood-brain barrier, treatment-resistant depression, functional connectivity, psychedelic research, neuroinflammation, default mode network, serotonergic system, clinical trial biomarkers, MRI neuroimaginghttps://mindmedicinelaw.com/briefing/antidepressants-cognition-and-psychedelics-precision-medicine-for-mdd-20261013-50976The Psychedelic Journalen2026-10-17T22:04:49.478024+00:00Antidepressants, Cognition, and Psychedelics: Precision Medicine for MDDantidepressants, cognitive function, major depressive disorder, psychedelic compounds, ketamine, clinical trial design, precision medicine, vortioxetine, regulatory guidancehttps://mindmedicinelaw.com/briefing/esketamine-s-neurobehavioral-impact-in-zebrafish-preclinical-insights-and-clinic-20261013-50652The Psychedelic Journalen2026-10-16T22:04:19.721464+00:00Esketamine’s Neurobehavioral Impact in Zebrafish: Preclinical Insights and Clinical Implicationsesketamine, zebrafish, neurobehavioral effects, preclinical research, nmda receptor antagonists, neurotoxicity, clinical translation, psychiatric safety, dose-dependent effectshttps://mindmedicinelaw.com/briefing/neuroplasticity-and-subjective-experience-in-psychedelic-therapy-systematic-revi-20261013-50640The Psychedelic Journalen2026-10-16T15:06:16.761741+00:00Neuroplasticity and Subjective Experience in Psychedelic Therapy: Systematic Review Insights (Global, 2026)psychedelic-assisted psychotherapy, neuroplasticity, subjective experience, clinical trials, policy implications, mechanistic research, depression treatment, hallucinogenic effects, biomarkers, therapeutic protocolshttps://mindmedicinelaw.com/briefing/psilocybin-safety-compliance-washu-study-and-policy-implications-20261012-50707The Psychedelic Journalen2026-10-16T22:04:41.236693+00:00Psilocybin Safety Compliance: WashU Study and Policy Implicationspsilocybin safety, washington university study, psychedelic regulation, provider compliance, policy implications, clinical protocols, public health, regulated psychedelic services, risk management